These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29472546)

  • 1. CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL.
    Kim JH; Kim WS; Ryu KJ; Kim SJ; Park C
    Blood Cancer J; 2018 Feb; 8(2):23. PubMed ID: 29472546
    [No Abstract]   [Full Text] [Related]  

  • 2. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
    Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
    Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
    Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
    Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
    Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
    Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.
    Du H; Gao L; Luan J; Zhang H; Xiao T
    Acta Haematol; 2019; 142(2):64-70. PubMed ID: 31096215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
    Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
    Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Li J; Qian C; Zhou Q; Li J; Li K; Yi P
    Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expressions of VEGF and CXCR4 in diffuse large B cell lymphoma and their clinical significances].
    Guo Q; Wang JJ; Li F; Yang HL; Yu Y; Zhao ZG; Wang XF; Wang YF; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):383-6. PubMed ID: 23628037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.
    Dubanet L; Bentayeb H; Petit B; Olivrie A; Saada S; de la Cruz-Morcillo MA; Lalloué F; Gourin MP; Bordessoule D; Faumont N; Delage-Corre M; Fauchais AL; Jauberteau MO; Troutaud D
    Br J Cancer; 2015 Sep; 113(6):934-44. PubMed ID: 26284337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
    Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
    Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.
    Young RM; Wu T; Schmitz R; Dawood M; Xiao W; Phelan JD; Xu W; Menard L; Meffre E; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Staudt LM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13447-54. PubMed ID: 26483459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
    Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
    Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
    Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas.
    Hirpara JL; Loh T; Ng SB; Chng WJ; Pervaiz S
    Oncotarget; 2016 Dec; 7(51):83964-83975. PubMed ID: 27863378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
    Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
    Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
    Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
    Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.
    He S; Miao X; Wu Y; Zhu X; Miao X; Yin H; He Y; Li C; Liu Y; Lu X; Chen Y; Wang Y; Xu X
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):561-72. PubMed ID: 26498772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
    de Jong MRW; Visser L; Huls G; Diepstra A; van Vugt M; Ammatuna E; van Rijn RS; Vellenga E; van den Berg A; Fehrmann RSN; van Meerten T
    PLoS One; 2018; 13(2):e0193098. PubMed ID: 29489886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.